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Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disorder with no
effective treatment currently available. Although the mechanisms of motoneuron (MN)
death are still unclear, glutamate excitotoxicity and neuroinflammatory reaction are two
main features in the neurodegenerative process of ALS. Neuregulin 1 (NRG1) is a trophic
factor highly expressed in MNs and neuromuscular junctions. Several recent evidences
suggest that NRG1 and their ErbB receptors are involved in ALS. However, further
knowledge is still needed to clarify the role of the NRG1-ErbB pathway on MN survival.
In this study we used an in vitro model of spinal cord organotypic cultures (SCOCs)
subject to chronic excitotoxicity caused by DL-threo-β-hydroxyaspartic acid (THA) to
characterize the effect of NRG1 on MN survival. Our results show that addition of
recombinant human NRG1 (rhNRG1) to the medium significantly increased MN survival
through the activation of ErbB receptors which was ablated with lapatinib (LP), an
ErbB inhibitor, and reduced microglial reactivity overcoming the excitotoxicity effects.
rhNRG1 activated the pro-survival PI3K/AKT pathway and restored the autophagic flux
in the spinal cord culture. Moreover, addition of rhNRG1 to the medium promoted motor
and sensory neurite outgrowth. These findings indicate that increasing NRG1 at the
spinal cord is an interesting approach for promoting MN protection and regeneration.
Keywords: neuregulin 1, ErbB receptors, motoneuron, excitotoxicity, spinal cord, organotypic culture,
amyotrophic lateral sclerosis, neurite growth
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common form of motoneuron (MN) disease,
characterized by the loss of MNs of primary motor cortex, brainstem and spinal cord (Wijesekera
and Leigh, 2009). Most patients with ALS die within 3–5 years after symptoms onset due to
respiratory failure (Robberecht and Philips, 2013). Unfortunately, there is no therapy for this
disease, and the only drugs approved for use in ALS, riluzole and edaravone, only slightly prolong
patients’ survival. The etiopathogenesis of ALS remains to be elucidated, but it has been proposed
that a complex interplay between excitotoxicity, neuroinflammation, oxidative stress, protein
aggregation and mitochondrial dysfunction contribute to MN degeneration (Robberecht and
Philips, 2013; Mancuso and Navarro, 2015). Among these pathogenetic mechanisms, excitotoxicity
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is considered as a firm mechanism involved in the disease
because of data obtained from ALS patients and animal and
cellular models as well as inferred by the therapeutic effect
of riluzole, an antiglutamatergic drug. The importance of
excitotoxicity in MN death has been demonstrated in ALS
mouse models in which excessive extracellular glutamate levels
contribute to MN loss (Van Damme et al., 2005). Several
in vitro models have been used to study glutamate neurotoxicity.
Among them, the spinal cord organotypic culture (SCOC)
offers advantages for assessing MN degeneration and potential
therapeutic agents (Herrando-Grabulosa et al., 2016). This model
is based on the selective inhibition of glutamate transport which
continuously raises the concentration of glutamate in the culture
medium, resulting in a slow degeneration of spinal MNs over
several weeks (Rothstein et al., 1993).
Neurotrophic factors derived from alternatively spliced
forms of the neuregulin 1 (NRG1) gene have been shown
to play an important role in peripheral nerve development
and regeneration, myelination, maintenance of neuromuscular
junctions, and also on microglial activation in peripheral nerve
diseases, whereas ablation of NRG1 impairs axonal regeneration
(Mei and Nave, 2014). NRG1 acts through the EGF domain
of ErbB receptors, a family of tyrosine kinase transmembrane
receptors. NRG1 is localized in the MN endomembrane
system, destined to be anterogradely transported either for
axon-Schwann cell signaling or for delivery to the neuromuscular
junction. Interestingly, NRG1 has been found present within
the subsurface cistern in postsynaptic sites of cholinergic C
terminals apposed to spinal MNs (Issa et al., 2010; Gallart-
Palau et al., 2014). ErbB2 and ErbB4 receptors are present in
the presynaptic compartment, suggesting that NRG1 acts as a
retrograde signaling molecule in MNs synaptic connections. A
role of NRG1 expressed in C synaptic boutons was recently
suggested for ALS, since spinal MNs showed a transient increase
of NRG1 during disease progression in SOD1G93A mice, whereas
oculomotor MNs, which are spared in ALS, lack both C boutons
and associated NRG1 (Gallart-Palau et al., 2014). In fact, it was
recently reported that viral-mediated delivery of type III-NRG1
to the spinal cord restored the number of C-boutons and slightly
extend the survival of SOD1 transgenic mice (Lasiene et al.,
2016).
Alterations in the NRG1/ErbB system have been related
to MN degeneration and ALS. Loss-of-function mutations
on the NRG1 receptor ErbB4 produce late-onset, autosomal-
dominant ALS in human patients (Takahashi et al., 2013).
NRG1 type III expression was found reduced in both ALS
patients and SOD1G93A mice in parallel with MN loss, but
NRG1 type I was increased and associated with glial activation
(Song et al., 2012). We recently reported that increased
expression of NRG1 in skeletal muscle promotes collateral
reinnervation and neuromuscular junction maintenance
in the SOD1G93A mouse model of ALS (Mancuso et al.,
2016).
Our goal in this study was to evaluate the role of NRG1 in
the SCOC subjected to chronic excitotoxicity, in order to assess
the potential effects of exogenous NRG1 on MN survival and
regeneration, and its mechanisms of action.
MATERIALS AND METHODS
Spinal Cord Organotypic Cultures for
Assessment of Neuroprotection
SCOCs were prepared on the basis of the method previously
described (Rothstein et al., 1993). The experimental procedure
was approved by the Ethics Committee of Universitat Autònoma
de Barcelona and followed the European Communities Council
Directive 2010/63/EU. P8 Sprague-Dawley rats were used in this
study. After euthanasia, the spinal cord was aseptically harvested
and placed in ice-cold high glucose-containing (6.4 mg/mL)
Gey’s Balanced Salt Solution (GBSS; Sigma-Aldrich, St. Louis,
MO, USA), and meninges were removed. The spinal cord was
cut transversely in 350 µm thick slices using a McIlwainTissue
Chopper (The Mickle Laboratory Engineering Co., Surrey, UK).
To investigate MN survival, glial reactivity and the ErbB
and signaling pathways activation SCOCs were obtained from
at least three independent cultures performed at different days
and resulting in 12 slices for condition. L4-L5 lumbar sections
were carefully transferred on Millicell-CM porous membranes
(0.4 µm; Millipore, Burlington, MA, USA) into a six-well
plate containing 1 mL of incubation medium (50% minimal
essential medium (MEM), 25 mM Hepes, 25% heat-inactivated
horse serum, 2 mM glutamine, and 25% Hank’s Balanced Salt
Solution (HBSS) supplemented with 25.6 mg/ml glucose; pH 7.2).
Cultures were let to stabilize for 1 week. During the first week
in a SCOC, a high number of neurons die naturally and glial
cells show strong reactivity due to the axotomy performed during
the culture procedure, which later stabilize. Then DL-threo-
β-hydroxyaspartic acid (THA; 100 µM) was added to induce
chronic excitotoxicity (Corse et al., 1999). Concomitantly, some
slices were treated with recombinant human NRG1 (rhNRG1;
100 ng/ml) or with lapatinib (LP), an ErbB blocker, at two
different concentrations (6 µM and 12 µM). PRE084 (10 µM)
a sigma-1 receptor agonist that promotes neuroprotection and
neurite elongation was used as a positive control (Guzmán-Lenis
et al., 2009). THA and the treating compounds were renewed at
each medium exchange, twice per week until 14 days in vitro
(DIV) for western blot analysis and histological stainings, or to
28 DIV for MN survival and microglial reactivity analyses. In
this model of chronic excitotoxicity, THA induces around 40%
of MN death after 3 weeks of treatment (28 DIV; Rothstein et al.,
1993), whereas microglial activation occurs after 2 weeks of THA
treatment (21 DIV) and is maintained at 28 DIV (Lee et al., 2012).
Protein Extraction and Western Blot
SCOC slices were prepared for protein extraction and
homogenized in modified RIPA buffer (50 mM Tris–HCl
pH 7.5, 1% Triton X-100, 0.5% sodium dodecyl sulfate (SDS),
100 mM NaCl, 1 mM EDTA) adding 10 µl/ml of Protease
Inhibitor cocktail (Sigma) and PhosphoSTOP phosphatase
inhibitor cocktail (Roche). Twenty to forty microgram of
protein of each sample were loaded in SDS-polyacrylamide
gels at different percentages (7.5%–15%). For heavy proteins
(ErbB receptors) the western blot transfer was applied 3.5 h
at room temperature with constant intensity of 360 mA. For
the rest of the proteins the transfer was made 1 h at room
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temperature with constant voltage of 90 V. The membranes
were blocked with 5% BSA in TBS plus 0.1% Tween-20 for
1 h, and then incubated with primary antibodies at 4◦C
overnight. The primary antibodies used were: anti-NRG1
(1:200, sc-228916, Santa Cruz Biotechnology), anti-ErbB4
(1:500, 4795S, Cell Signaling), anti-ErbB3 (1:500, 12708S,
Cell Signaling), anti-ErbB2 (1:500, 4290S, Cell Signaling),
anti-pErbB4 (1:500, 4757S, Cell Signaling), anti-pErbB3
(1:500, 2842S, Cell Signaling), anti-pErbB2 (1:500, 2243L, Cell
Signaling), anti-Akt (1:1000, 4691S, Cell Signaling), anti-pAkt
(1:1000, 4060, Cell Signaling), anti-ERK1/2 (1:500, 4348,
Cell Signaling), anti-pERK1/2 (1:500, 9106, Cell Signaling),
anti-LC3 (1:500, ab51520, Abcam), anti-p62 (1:500, 610833, BD
Biosciences), anti-Beclin 1 (1:1000, ab62557, Abcam), anti-Actin
(1:10,000, A5316, Sigma) and anti-GAPDH (1:10,000, MAB374,
Millipore). Horseradish peroxidase-coupled secondary antibody
(1:3000; Vector Laboratories, Burlingame, CA, USA) incubation
was performed for 1 h at room temperature. The membranes
were visualized using enhanced chemiluminescence method and
the images were collected using a Chemidoc apparatus. Western
blots were then analyzed using the Lane and Band plugin from
the Image Lab software (BioRad), and normalized first by the
loading control (actin and GAPDH) and afterwards by each
control sample. Each sample analyzed was extracted from
four slices and 3–7 samples were analyzed per each treatment
condition.
Immunoflurorescence Analyses
We fixed slices in the different experimental conditions with
4% paraformaldehyde in PBS for 1 h at RT. After blocking
with 5% normal horse serum (Vector Laboratories, Burlingame,
CA, USA) and 0.3% Triton-X-100 in TBS (TBS-TX), we
incubated the sections for 48 h with primary antibodies against
anti-neurofilament H non-phosphorylated (SMI-32, 1:1000,
BioLegend) or anti-ionized calcium binding adapter molecule
1 (Iba-1, 1:1000; Wako, Japan). Slices were thoroughly washed
in TBS with 0.1% Tween-20 (TBS-T) and incubated with
the appropriate secondary antibody Alexa Fluorr488 donkey
anti-rabbit IgG (1:500) and Alexa Fluorr594 donkey anti-mouse
IgG (1:500; Invitrogen, Carlsbad, CA, USA), diluted in TBS-T for
2 h. Finally, cell nuclei were labeled with DAPI (1:2000) for 1 min
in TBS and the sections mounted with Fluoromount-G medium
(SouthernBiotech, Birmingham, AL, USA). We analyzed the
slides under confocal microscopy, and counted the SMI-32
positive cells in each hemislice using the tool Cell Counter from
ImageJ software (NIH)1. MNs were selected according to the
following criteria: localization in ventral horns and polygonal
shape, with clear dendrites. To quantify the microglia, we selected
the ventral zone using for each image the same area, and then
quantified the integrated density (area of the ROI ×mean of the
ROI) using the ROI manager tool of ImageJ.
Immunohistochemical Analyses
Slices were fixed with 4% paraformaldeyde in PBS for 24 h
at 4◦C, and then, cryoprotected in 30% sucrose in PBS and
1http://rsb.info.nih.gov/ij/
stored at 4◦C. Cyroprotected slices were then sectioned with
a cryostat (Leica) into 6–8 10 µm thick sections from each
SCOC. The endogenous peroxidase activity was inhibited (70%
Methanol, 30% TBS 1X, 2% H2O2) and thereafter a blocking
solution (5% normal horse serum and 1% BSA in TBS-T) was
added. We incubated the slides overnight at 4◦C with primary
antibodies against anti-ErbB4 (1:100, 4795S, Cell Signaling)
and anti-ErbB2 (1:100, 4290S, Cell Signaling). Slides were
washed with TBS-T and incubated with a secondary antibody
horse anti rabbit HRP conjugate (Vector Laboratories, USA)
overnight at 4◦C. Afterwards, we incubated the slides with the
VECTASTAINr Eliter ABC complex (Vector Laboratories,
USA) for 1 h at RT and a DAB solution (Vector Laboratories,
USA) was used for brown color development. We finally
counterstained the slides with cresyl violet to localize the MNs
in the ventral horn.
Organotypic Cultures for Assessment of
Neurite Growth
For assessing neurite outgrowth, we used spinal cord sacral
sections and also dorsal root ganglia (DRG) explant cultures
(n = 11/group) embedded in a collagen gel, as previously
described (Allodi et al., 2011; Santos et al., 2016). Collagen
type I solution (#354236, Corning) at a concentration of
3.83 mg/ml was mixed with basal Eagle’s medium (Gibco) and
7.5% of sodium bicarbonate solution. NRG1 at a concentration
of 100 ng/ml was added to the collagen gel in the treated
slices, whereas the same volume of PBS was used for the
control slices. Single 30 µl drops were deposited on poly-D-
lysine (1 g/ml, Sigma) coated coverslips, which were placed
in 24-well multidishes (Iwaki, Asahi Technoglass, Chiba,
Japan) and kept in the incubator for 2 h to induce collagen
gel formation. Spinal cord slices and DRG explants were
then embedded in the gelled collagen droplets, and placed
in the incubator for 45 min before adding Neurobasal
medium (NB, Invitrogen), supplemented with B27 (Invitrogen),
glutamine and penicillin/streptomycin (Sigma). After 1 day
in culture, the medium of spinal cord cultures was removed
and changed by a penicillin/streptomycin free medium. DRG
explants were cultured for 2 days, and spinal cord slices
for 4 days.
Neurite Growth Analysis
Spinal cord and DRG cultures were fixed with 4%
paraformaldehyde in PBS for 30 min. Afterwards, the
samples were incubated for 48 h with primary antibody
mouse RT97 that recognizes phosphorylated epitopes of
neurofilaments (1:200, Developmental Studies Hybridoma
Bank) at 4◦C, washed and incubated with secondary antibody
AF594 conjugated donkey anti-mouse (1:200, Jackson IR)
overnight at 4◦C. After two washes samples were mounted on
slides with Mowiol containing DAPI (1:10,000, Sigma) nuclear
counterstain.
Cultures were visualized with an Olympus BX51 fluorescence
microscope, images of different areas were taken with Cell A
software (Olympus) and merged using Adobe Photoshop CS3
(Adobe System). Whole culture images were analyzed with the
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FIGURE 1 | Recombinant human NRG1 (rhNRG1) promotes motoneuron (MN) survival in the spinal cord organotypic culture (SCOC) under excitotoxicity.
(A) Representative microphotographs of MNs in the ventral horn of the slices labeled with the SMI-32 antibody and DAPI at 28 days in vitro (DIV). Cultures were
subjected to excitotoxicity by DL-threo-b-hydroxyaspartic acid (THA) alone or co-treated with rhNRG1 with or without lapatinib (LP) inhibitor, or with PRE084, a
sigma 1 receptor agonist used as a positive control. Scale bar = 50 µm. (B) Microphotograph of a spinal cord slice in culture at 28 DIV is shown. Histogram graph
showing the number (mean ± SEM, n = 24–31 hemisections per treatment) of SMI-32 positive cells in the ventral horn of each spinal cord slice. ∗∗∗p < 0.001;
∗∗p < 0.01; ∗p < 0.05. (C) Western blot of the Neuregulin 1 (NRG1) protein in SCOCs under control or THA condition at 14 DIV. Bar graph showing the mean ± SEM
protein levels of NRG1 (n = 3 cultures per condition). ∗p < 0.05.
Neurite-J plug-in (Torres-Espín et al., 2014) for ImageJ software
and the number of neurites grown at 50 µm intervals from
the explant was compared between sets of cultures. The length
measured for each neurite was the distance from the end of
the neurite straight back to the DRG body radially (Deister and
Schmidt, 2006) or to the neuronal body in spinal cord slices
(n = 10–15 per slice).
Data Analysis
Data were evaluated using GraphPad Prism 5 software (San
Diego, CA, USA). For statistical analysis, immunofluorescence
data were analyzed by one-way ANOVA followed by Bonferroni
multiple post hoc comparisons test. Western blot quantification
results were analyzed by two-tail unpaired t-test for two groups
comparison and one-way ANOVA followed by Tukey multiple
post hoc test for multiple group comparison. Data were expressed
as mean ± SEM. For the neurite length assessment, results
were analyzed by performing a two-tailed unpaired t-test.
All differences were considered statistically significant when
p< 0.05.
RESULTS
rhNRG1 Prevents Motoneuron Cell Death
In SCOCs prepared for the assessment of neuroprotection,
addition of THA in the medium significantly reduced the
number of SMI32 positive cells in the ventral horn (21 ± 1)
compared to the control slices (30 ± 2; Figures 1A,B). We also
evaluated by western blot the endogenous level of NRG1 in
the SCOCs after chronic excitotoxicity, and found that after
21 days of exposure to THA, NRG1 levels were significantly
reduced (0.51± 0.05) compared to control cultures (0.85± 0.15;
Figure 1C). With the aim to investigate if NRG1 could act
as a neuroprotective agent for spinal cord MNs, we added
100 ng/mL of rhNRG1 to the SCOCs exposed to THA, and found
significant preservation of MNs (30± 1) at similar level than with
addition of PRE084 (29± 2; Figures 1A,B). The neuroprotective
effect induced by rhNRG1 alone was abolished by simultaneous
treatment with LP, an ErbB blocker, at 12 µM (20 ± 2) and
partially at 6 µM (24 ± 1; Figure 1B). Addition of LP alone at
6 µM and 12 µM had no influence on the loss of MNs induced by
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FIGURE 2 | ErbB receptors activation. Western blot of SCOCs revealed an increased phosphorylation ratio of ErbB2 (A), ErbB3 (B), and ErbB4 (C) receptors upon
rhNRG1 treatment, that was totally or partially blocked by co-addition of LP. Data are shown as mean ± SEM with n = 3–5 values per treatment. ∗∗p < 0.01;
∗p < 0.05. (D) Microphotographs of ErbB2 and ErbB4 protein labeling with DAB and cresyl violet in control SCOCs at 14 DIV. Inset show MNs labeled against ErbB
receptor at higher magnification. Scale bar = 100 µm.
THA (20± 2 and 18± 2, respectively). These results indicate that
rhNRG1 induces protection to MNs under an excitotoxic chronic
insult through ErbB receptors.
rhNRG1 Signaling under Chronic
Excitotoxicity
In order to evaluate the signaling pathways underlying the
neuroprotective effect of rhNRG1, we performed immunoblot
analyses of the ErbB receptors. The total isoform expression
of ErbB2, 3 and 4 receptors was not significantly modified in
the different SCOC conditions as measured by immunoblot.
However, excitotoxicity caused a significant reduction of the
proportion of activated ErbB2 and ErbB4 and not significant
for ErbB3 in comparison with control cultures (Figure 2). The
activation of ErbB receptors was determined by calculating
the ratio between the phosphorylated vs. the total protein
levels. Interestingly, the level of phosphorylated ErbB receptors
was restored by addition of rhNRG1 to the culture medium
(Figure 2). On the other hand, addition of LP at 12 µM
significantly inhibited the activation of ErbB2 induced by
rhNRG1, and tended to block although not significantly the
levels of phosphorylated ErbB3 and ErbB4 receptors (Figure 2).
In addition, histological staining was performed to localize the
ErbB receptors in the ventral horn of control SCOC. We confirm
that ErbB2 and ErbB4 are expressed in MNs in the spinal cord
slices taken at 14 DIV. The ErbB2 expression pattern was similar
to that in intact, non-cultured, spinal cord. ErbB4, which is
located in the cytosol of the MNs, appeared partly distributed
to the nucleus after the axotomy produced for the culture
(Figure 2D).
To corroborate the functional activation of the ErbB
receptors through NRG1 signaling, we analyzed changes in the
phosphorylation levels of AKT and ERK1/2, as downstream
targets of ErbB related to neuronal survival. Increased
activation of AKT by rhNRG1 treatment was evidenced by
the significantly higher ratio of the phosphorylated vs. the
total form of the protein compared to addition of THA
alone (Figures 3A,C). In contrast, we did not find significant
changes in the activation of ERK1/2 (Figures 3B,C). Because
AKT pathway can modulate macroautophagic mechanisms,
we examined the expression of different markers. Upon
rhNRG1 treatment, we found a reduction of Beclin 1, a
phagophore formation marker, and of p62, a protein involved
in the proteasomal degradation of ubiquitinated proteins,
compared to the increase produced by THA treatment alone,
although the differences were not significant (Figures 4A,B).
Interestingly we found differences in the LC3-II, a marker
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FIGURE 3 | Activation of downstream targets by rhNRG1. (A,C) Western blot of SCOCs revealed increased phosphorylation of AKT upon rhNRG1 treatment
compared to the excitotoxic treatment alone. (B,C) No significant differences for ERK activation. Data are shown as mean ± SEM with n = 3–5 values per treatment.
∗∗p < 0.01; ∗p < 0.05.
of autophagosome formation. Under chronic excitotoxicity
the LC3-II levels were enhanced, whereas addition of
rhNRG1 maintained the levels of LC3-II similar to the control
condition (Figure 4C).
rhNRG1 Reduces Microglial Reactivity
We also analyzed whether rhNRG1 had a role modulating
the microglial activation in the SCOC. Microglial reactivity
markedly increased with THA treatment, as revealed by the
integrated density of Iba-1 labeling (5.19 × 109 ± 8.30 × 108)
at 28 DIV (Figure 5). Addition of rhNRG1 under
chronic excitotoxicity significantly reduced microgliosis
(2.70 × 109 ± 4.98 × 108) at the same level than control slices
(2.41 × 109 ± 4.86 × 108). PRE084 caused a less marked
reduction of microglial reactivity that did not reach significance
(3.41× 109 ± 8.40× 108).
rhNRG1 Enhances Motor and Sensory
Neurite Outgrowth
Because we observed in rhNRG1-treated slices a larger bundle
of tangled axons than in control slices, we assessed whether
rhNRG1 might influence neurite growth by using modified
organotypic culture models (Figures 6A,B; Allodi et al., 2011).
rhNRG1 treated SCOCs showed significantly higher number
of growing motor neurites and increased average length
of the longest neurites (694 ± 82 µm) compared to the
untreated control cultures (271 ± 16 µm; Figures 6E,F).
Additionally, we also evaluated the role of rhNRG1 on sensory
neurite elongation (Figures 6C,D). rhNRG1-treated DRG also
showed increased number of growing sensory neurites and
length of the longest neurites (945 ± 42 µm) compared to
control cultures (677 ± 42 µm; Figures 6G,H). However,
the effect was less marked for sensory than for motor
neurites.
DISCUSSION
The results of this study demonstrate that NRG1 exerts
neuroprotective effects on MNs under chronic excitotoxicity,
and also enhances neurite growth. These properties point to
the NRG1-ErbB system as a potential target of interest for the
treatment of MN degenerative diseases.
We used two relevant models of neural organotypic cultures
in order to independently assess these two actions in vitro. The
SCOC has the advantage to preserve the anatomical organization
of the spinal cord, neuronal connectivity and glial–neuronal
interactions. The SCOC model under chronic excitotoxicity
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FIGURE 4 | Autophagic flux modulation by rhNRG1. Western blot of SCOCs did not show significant changes for Beclin 1 (A) and p62 (B). However, THA induced
an increase of autophagosome marker LC3II (C), which was prevented when rhNRG1 was applied to the SCOCs. Data are shown as mean ± SEM with
n = 3–7 values per treatment. ∗∗p < 0.01; ∗p < 0.05.
induced by THA is an in vitro model based on the role of
glutamate toxicity. It has been proved a useful in vitro model
for screening potential therapeutic drugs (Guzmán-Lenis et al.,
2009; Herrando-Grabulosa et al., 2016; Pandamooz et al., 2016)
against MN degeneration that does not depend on known genetic
alterations, thus being relevant for the majority of sporadic
ALS cases and other MN diseases. The role of NRG1 and its
isoforms on the ALS pathogenesis is still controversial. The
studies investigating the expression of NRG1 and its ErbB
receptors in the spinal cord have reported several alterations
in samples of mouse models and ALS patients. Regarding the
mRNA levels of NRG1, the Type III isoform was found decreased
in the ventral horn of the spinal cord from ALS human samples
as well as in SOD1G93A transgenic mice in parallel with MN
loss, whereas the Type I isoform was reported to increase
at advanced stage of the disease in SOD1G93A mice in one
study (Song et al., 2012) and to decrease in another (Lasiene
et al., 2016). In the SCOCs under chronic excitotoxicity we
found low expression of NRG1 compared to control slices, and
addition of exogenous NRG1 significantly preserved the number
of surviving MNs in the ventral horn. The rhNRG1 corresponds
to the EGF-domain of NRG1, which is able to activate ErbB
receptors 2, 3 and 4. The EGF-domain of NRG1 can bind
to ErbB3 and ErbB4 by inducing their homodimerization or
the heterodimerization with ErbB2. As a consequence of the
dimerization ErbB receptors phosphorylate. We showed that the
neuroprotective effects of rhNRG1 are mediated by the activation
of ErbB receptors because the addition of LP, an inhibitor of
ErbB receptors, blocks the neuroprotective action of rhNRG1.
In addition we showed that the ErbB2 and ErbB4 receptors are
expressed in MNs, although we could not confirm the expression
of ErbB3 due to limitations of the antibodies available. The
ErbB2 pattern was the same as previously shown at in vivo
samples (Song et al., 2012), while ErbB4 appeared in the nucleus
of the MNs after the axotomy produced in the culture. Upon
phosphorylation of ErbB receptors, the PI3K-AKT pro-survival
pathway was activated as demonstrated by immunoblot. In
cultures of embryonic rat MNs, NRG1 was shown to inhibit
apoptosis during the period of embryonic programmed cell death
by a PI3K-dependent pathway, although in this case it did not
increase the relative level of p-AKT (Ricart et al., 2006). Despite
the fact that ERK pathway is another cascade induced upon ErbB
receptor activation, no differences of ERK1/2 were detected after
rhNRG1 treatment.
Autophagy is another common feature in MN diseases
that has already been described in the SCOC under chronic
excitotoxicity (Matyja et al., 2005; Herrando-Grabulosa et al.,
2013). However, the role of autophagy in promoting neuronal
cell death or survival is a subject of debate. After THA treatment
we found evidence of accumulation of autophagosomes that
corresponds to an early stage of autophagy cell death induction.
In contrast, addition of rhNRG1 to the culture decreased
the levels of the phagopore formation marker Beclin 1 and
the autophagosome marker LC3-II. Therefore, rhNRG1 may
act restoring the autophagic flux by reducing the number
of autophagosomes formed and starting p62 degradation in
the lysosome after the fusion, avoiding accumulation in the
cytosol.
MNs are preferentially damaged by the prolonged
blockade of glutamate uptake produced by THA addition,
causing excitotoxicity. In the SCOC this mechanism is
mediated by non NMDA receptors, such as AMPA receptor
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 January 2018 | Volume 11 | Article 431
Mòdol-Caballero et al. Neuregulin 1 Beneficial Effects in Motoneuron Degeneration
FIGURE 5 | Reduction of microgliosis by rhNRG1. (A) Representative microphotographs showing microglia stained with anti-IBA1 (red), non-phosphorylated H
neurofilament SMI32 (green) and DAPI (blue) at 21 DIV post-THA treatment alone or co-treated with rhNRG1 (100 ng/ml) or PRE084 (10 µM). Scale bar = 50 µm.
(B) Higher magnification images of microglia stained with anti-IBA1 showing morphological differences between control, THA added and THA+ rhNRG1 conditions.
Scale bar = 10 µm. (C) Bar graph showing the microglial reactivity measured by the integrated density in the ventral horn of SCOCs (mean ± SEM,
n = 15 hemisections per treatment). ∗p < 0.05.
(Rothstein et al., 1993). While these channels permit rapid
Ca2+ entry, MNs buffer the consequent cytosolic Ca2+ load
poorly (Lips and Keller, 1998), with the consequence that
much of the Ca2+ is readily taken up into mitochondria,
resulting in strong reactive oxidative species (ROS) generation
(Carriedo et al., 2000; Rao et al., 2003). Furthermore, ROS
may be able to exit the MN, disrupting glutamate transport
in surrounding astrocytes, resulting in increased extracellular
glutamate accumulation, and further propagation of the injury
cascade (Rao et al., 2003; Yin and Weiss, 2012). Recently it has
been shown that NRG-1β plays an important role in modulating
Ca2+ homeostasis and preventing apoptosis through activating
PI3K/AKT pathway in DRG sensory neurons subjected to
excitotoxicity induced by glutamate (Liu et al., 2011). This
evidence suggests that in the SCOC, rhNRG1 treatment may
modulate Ca2+ homeostasis and thus reduce the excitotoxicity
through this mechanism.
On the other hand, we used SCOCs and DRG explants
embedded in a 3D collagen matrix, which creates a permissive
environment for neurite elongation (Allodi et al., 2011; Santos
et al., 2016), to assess the effects of NRG1 on neurite growth.
Our results showed that rhNRG1 increased the number and
length of the neurites emerging from both motor and sensory
neurons in the SCOC and DRG cultures respectively. NRG1 plays
an important role in myelination during development and
also after injury in the peripheral nerve, and promotes the
role of Schwann cells supporting axonal regeneration (Fricker
and Bennett, 2011; Gambarotta et al., 2013; Stassart et al.,
2013). Immediately after injury, the soluble NRG1 transcript
is upregulated in the lesioned nerve, mostly released by
reactive Schwann cells (Stassart et al., 2013), suggesting that
soluble NRG1 plays a role also during the early phases of
axonal degeneration and regrowth (Gambarotta et al., 2013).
NRG1 receptors ErbB2, ErbB3 and ErbB4 are variably expressed
by adult DRG sensory neurons and spinal cord MNs, and
their levels increase although in a variable pattern after their
axotomy, indicating that NRG1 proteins may act directly on the
neurons (Pearson and Carroll, 2004). In our in vitro organotypic
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FIGURE 6 | rhNRG1 enhances neurite outgrowth. Representative microphotographs of untreated and rhNRG1-treated SCOC (A,B) and dorsal root ganglia (DRG)
(C,D) cultures embeeded in collagen. Graphs show the number of neurites per intersection and the maximum neurite length in the SCOC (E,F) and the DRG (G,H)
cultures. Scale bar = 500 µm. Data are shown as mean ± SEM with n = 11 slices per treatment. ∗p < 0.05.
cultures, addition of exogenous NRG1 promoted the initial
phase of neurite growth, likely acting on the neuronal processes.
Accordingly, increased supply of exogenous NRG1 was shown
to promote nerve regeneration in vivo (Chen et al., 1998;
Nicolino et al., 2003; Joung et al., 2010). Our group has
also recently reported that intramuscular administration of
NRG1 Type 1 enhances the emergence of collateral sprouts
of motor axons that reinnervate previously denervated muscle
fibers in wild type and SOD1G93A mice (Mancuso et al.,
2016).
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Another relevant aspect in the issue is whether the
NRG1-ErbB pathway participates in the regulation of the
neuroinflammatory response mediated by microglial cells, a
common feature that occurs in human patients as well as in
murine models of neurodegeneration. Activated ErbB2 receptors
predominantly present on microglia and, to a lesser extent,
on astrocytes were found overexpressed as a function of
disease progression in the SOD1G93A transgenic mouse,
correlating with the pattern of microglial activation (Song
et al., 2012). These findings led to suggest that NRG1 isoforms
could contribute to disease pathogenesis through glial cell
activation. Chronic excitotoxicity also induced a marked
microglial response in the SCOC that was markedly reduced
by administration of rhNRG1. Furthermore, we observed
that microglial cells showed thinner and more ramified
processes under rhNRG1 treatment compared to THA alone
where microglia had an ameboid morphology and larger
size. These results suggest that in this chronic excitotoxic
model, rhNRG1 modulates the ErbB2 receptor expressed in
microglia. Indeed, NRG1 signaling via the ErbB2 receptor
was shown to be involved in microglial proliferation and
chemotaxis after peripheral nerve injury (Calvo et al.,
2010).
Recently, it has been reported that autophagy might
influence inflammation and activation of microglia, as well as
inflammation might promote or inhibit the process of autophagy
(Su et al., 2016). Interestingly, IGF-I has been described to
protect hippocampal neurons against early excitotoxicity via
the NR2B/PI3K-AKT-mTOR pathway, suppressing the excess
of autophagy (Wang et al., 2014). Considering these links
between the different pathogenic mechanisms we hypothesize
that rhNRG1 reduces the autophagy caused by excitotoxicity
activating the ErbB receptors and the PI3K/AKT pathway in
both MNs and microglial cells. This activation promotes a
dual effect; the survival of the MNs and the reduction of
the neuroinflammatory response mediated by the microglia.
Therefore, the modulation of the expression of NRG1 at the
central nervous system seems an interesting approach for
promoting neuroprotection and maintenance of connectivity of
the MNs.
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